Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsAetna Medicare Advantage Part B preferred drugs | …
    Ask Trek AI about this page

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    CurrentAetnaPolicy N/A

    Medicare Part B preferred drug list — Aetna Medicare Advantage (MA) only plans

    Customize your policy alerts

    Sign up for all Aetna policy alerts

    Know when Aetna releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Aetna's Medicare Advantage (MA) Part B preferred drug list describing preferred and non-preferred medically administered (Part B) drugs, applicable utilization management (e.g., step therapy, prior authorization) and HCPCS codes for providers and administrators.

    Policy Summary
    PayerAetna
    PolicyMedicare Part B preferred drug list — Aetna Medicare Advantage (MA) only plans
    Policy CodePolicy N/A
    Change TypeNo material changes
    Effective DateN/A
    Next Review DateN/A
    Key ActionUse the linked medical necessity criteria and fax prior authorization forms when requesting non-preferred or PA-required Part B drugs.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    20+drug categories & product entries
    HCPCSHCPCS codes mapped
    step therapy notedindications with step therapy
    variesprior authorization status
    multiple
    entries link to criteria/forms
    ©2025copyright year

    Coverage criteria and product-specific rules

    inv-01: Bone resorption inhibitors - initial coverage logic

    Preferred products and step therapy rules for bone resorption inhibitors

    Bone resorption inhibitors preferred-before-nonpreferred: Preferred product from both tiers required prior to receiving a non-preferred product for listed indications (hypercalcemia of malignancy; prevention of skeletal events in multiple myeloma; prevention of skeletal events in prostate cancer or solid tumors with bone metastases; treatment of osteopenia or osteoporosis in systemic mastocytosis)

    Specific product-level step therapy criteria and links provided per drug

    inv-02: Alpha-1 proteinase inhibitors

    Alpha-1 antitrypsin deficiency products

    Alpha-1 products: Preferred products Prolastin-C and Zemaira (HCPCS J0256) are listed with links to medical necessity criteria and fax forms; other alpha-1 products (e.g., Aralast NP) are listed as non-preferred with criteria links

    Indication subject to step therapy; linked criteria referenced

    inv-03: Botulinum toxins

    Botulinum toxin coverage notes

    Botulinum toxins: Botox (J0585) and Xeomin (J0588) are noted as 'Prior authorization is not required' for listed indications (blepharospasm, cervical dystonia, chronic sialorrhea, upper limb spasticity); other botulinum products (Daxxify, Dysport, Myobloc) are non-preferred or require criteria/links

    Specific product-level step therapy or criteria links provided per product

    inv-04: Colony stimulating factors

    Colony stimulating factors

    CSFs: Neulasta (J2506) and biosimilar Fulphila (Q5108) are listed with 'Prior authorization is not required'; other colony stimulating factors and biosimilars are listed with links to medical necessity criteria and may have step therapy as indicated

    See linked criteria for product-specific requirements

    inv-05: Coverage notes for listed products

    Coverage and step therapy statements for listed erythropoiesis-stimulating agents and selected specialty drugs

    Erythropoiesis stimulating agents - preferred vs non-preferred: Preferred drugs include Procrit and Aranesp; non-preferred drugs include Epogen and Retacrit (HCPCS J0885 listed) and other alternatives. Some products (e.g., Reblozyl) have linked criteria and fax forms.

    Some indications are explicitly 'subject to step therapy' (e.g., anemia due to zidovudine; transfusion reduction for select surgeries)

    inv-06: Prior authorization / medical necessity distinctions

    Prior authorization and medical necessity link indications

    Prior authorization indicated: Aranesp (J0881) is noted as 'Prior authorization' under medical necessity criteria; Procrit (J0885) is shown as 'Prior authorization is not required' in this excerpt; Reblozyl and other products reference 'Link to criteria' and 'Link to fax form' for medical necessity documentation.

    Document provides external links to medical necessity criteria and fax request forms for many products

    inv-07: Step therapy / Prior authorization criteria (partial)

    Covered when meeting product-specific prior authorization and step therapy criteria (links referenced in document).

    Step therapy applicability: Entries are flagged as 'Indications subject to step therapy' for multiple conditions (examples include Crohn's disease, ulcerative colitis, psoriasis and other immunologic indications); coverage requires meeting the product-specific step therapy or medical necessity criteria linked for each drug.

    Providers must follow the linked criteria and fax forms where indicated

    inv-08: IV iron initial coverage

    Intravenous iron is covered when the following conditions are met

    IV iron coverage criteria: Patient has iron deficiency anemia AND either intolerance to oral iron or unsatisfactory response to oral iron OR has chronic kidney disease

    Certain IV iron products (Feraheme Q0139/Q0138, Injectafer J1439, Monoferric J1437) are listed with step therapy/linked criteria while other IV iron products (Ferrlecit J2916, sodium ferric gluconate J2916, Infed J1750, Venofer J1756) are noted as 'Prior authorization is not required'

    inv-09: Remicade and biosimilars

    Remicade and biosimilars coverage grouping

    Preferred biosimilars: Inflectra (Q5103) and Renflexis (Q5104) are listed with links to medical necessity criteria and fax forms and are identified as preferred in multiple indications; Avsola (Q5121) and Remicade (J1745) are listed with criteria links and may have step therapy noted per indication

    Non-preferred infliximab products may be subject to step therapy; see product-level links

    inv-10: Sample PA exceptions vs PA-required placeholders

    Mixed coverage/authorization statements present in excerpt; individual drug entries reference either 'Prior authorization is not required' or 'Link to criteria' indicating PA required.

    PA not required examples: Some agents are explicitly noted as 'Prior authorization is not required' in this excerpt (examples include Docetaxel J9171, Carboplatin J9045, select pemetrexed codes, and other chemotherapy/infusion agents); other agents list 'Prior authorization' or link to criteria indicating PA is required.

    Providers should consult the individual product rows for the PA status and use the linked fax forms/criteria when required

    inv-11: Rituximab and biosimilars - step therapy

    Step therapy application example

    Rituximab step therapy: All requests for rituximab and biosimilars are subject to step therapy except requests for rheumatoid arthritis, which are excluded from step therapy

    Document explicitly lists the rheumatoid arthritis exception for rituximab

    inv-12: Ophthalmic VEGF inhibitor tiering

    Coverage and prior authorization notes for categories and products

    VEGF inhibitors (ophthalmic) tiering: Preferred product from both tiers must be used prior to receiving a non-preferred ophthalmic VEGF product; bevacizumab (Avastin) is noted as 'Prior authorization is not required' while tiered preferred ophthalmic biologics (e.g., Byooviz) are listed for trial/failure sequencing

    Specific tiering and step therapy links are provided in the ophthalmic VEGF inhibitor entries

    inv-13: Product-specific prior authorization

    Prior authorization status varies by product

    Prior authorization presence: Some products explicitly state 'Prior authorization is not required' (for example bevacizumab/Avastin and selected pemetrexed codes), while others list 'Prior authorization' or provide 'Link to criteria' indicating that authorization may be required; providers should review individual product rows for specifics

    See the product-level 'Medical necessity criteria' and 'Fax request form' links for submission requirements

    Non-preferred products are identified in the policy listings. Approval for non-preferred agents is contingent on meeting the referenced product-level medical necessity and step therapy criteria linked in each drug row (for example, bone resorption inhibitors include preferred-first language and links to criteria for second‑tier or non‑preferred agents). Providers should follow the linked criteria for the specific non‑preferred product when submitting requests.

    The excerpt does not list plan-level exclusions for specific drugs within these chunks. For complete descriptions of benefits, exclusions, limitations, and conditions of coverage, refer to the plan's Evidence of Coverage as noted in the document.

    Several product entries explicitly note that Prior authorization is not required for specific drugs in the excerpt. Examples include pamidronate and zoledronic acid in the bone resorption inhibitor category and multiple gonadotropin‑releasing hormone agonists (e.g., Lupron depot, Trelstar, Zoladex) which are shown with prior‑authorization not required language; other agents elsewhere (for example some chemotherapy drugs) are also marked as PA not required. Providers should verify the PA status on the individual product row and use the linked fax form/criteria when PA is required.

    Within the intravenous iron category some products are listed as preferred with Prior authorization is not required (e.g., Ferrlecit, sodium ferric gluconate, Infed, Venofer). Other IV iron formulations (Feraheme, Injectafer, Monoferric) are shown under non‑preferred or labeled with step therapy language and reference links to step therapy/criteria—meaning they may be excluded from preferred coverage unless the step therapy criteria are met.

    Requests for rituximab and its biosimilars are generally listed as subject to step therapy but the document explicitly exempts rheumatoid arthritis from that step therapy requirement: all requests except rheumatoid arthritis are subject to step therapy. This is an explicit exception to the step therapy requirement for that indication.

    There are no explicit item‑level exclusions called out in these chunks. The document directs readers to the Evidence of Coverage for a complete description of plan exclusions, limitations, and conditions of coverage.

    The excerpt does not contain explicit 'not medically necessary' determinations for specific drugs. Coverage decisions in this document are presented as conditional on meeting the product‑specific medical necessity and step therapy criteria referenced in each drug row.

    No explicit statements labeling specific drugs as 'not medically necessary' are provided in this excerpt. Providers should consult the linked product medical necessity criteria and the plan Evidence of Coverage for any determinations about non‑coverage.

    These chunks do not include explicit 'not medically necessary' language. The policy framework emphasizes that coverage is determined by meeting the listed medical necessity and step therapy criteria; plan exclusions and coverage limitations are referenced to the Evidence of Coverage.

    HCPCS/J-code mapping and code tables

    Alpha-1 proteinase inhibitors - Preferred HCPCSHCPCSCovered
    J0256Prolastin-C, Zemaira (alpha-1 proteinase inhibitors)
    Bone resorption inhibitors - mixed tiersHCPCSCovered
    J2430Pamidronate
    J3489Zoledronic acid
    J0897Xgeva
    Botulinum toxinsHCPCSCovered
    J0585Botox
    J0588Xeomin
    J0589Daxxify
    J0586Dysport
    J0587Myobloc
    Complement inhibitors / related biologicsHCPCSCovered
    J1299Soliris (eculizumab)
    J1303Ultomiris (ravulizumab)
    J1823Uplizna
    J9332Vyvgart
    J9334Vyvgart Hytrulo
    Colony stimulating factors (long and short-acting) and biosimilarsHCPCSCovered
    J2506Neulasta / Neulasta Onpro
    Q5108Fulphila
    J1447Granix
    J1442Neupogen
    Erythropoiesis stimulating agents and related productsHCPCSCovered
    J0885Epoetin products (Epogen/Procrit/Retacrit)
    J0882Reblozyl (luspatercept) HCPCS listed
    Erythropoiesis stimulating agents - Procrit/RetacritHCPCS
    J0885Procrit / Retacrit HCPCS code J0885 (as listed)
    Q5106Q5106 (listed alongside J0885)
    Aranesp / Reblozyl and related HCPCS entriesHCPCS
    J0881Aranesp HCPCS code J0881
    J0882Reblozyl HCPCS code J0882/J0881 (listed together in header)
    J0896Reblozyl HCPCS code J0896 (also referenced)
    Q4081Q4081/J0885 (listed)
    Q5105Q5105/Q5106 (listed)
    J0901J0901 (listed)
    Enzyme replacement and Factor VIII codesHCPCS
    J1786Cerezyme HCPCS code J1786
    J3060Elelyso HCPCS code J3060
    J7211Kovaltry HCPCS code J7211
    J7209Nuwiq HCPCS code J7209
    J7192Advate HCPCS code J7192
    J7210Afstyla HCPCS code J7210
    J7182NovoEight HCPCS code J7182
    J7185Xyntha HCPCS code J7185
    Geographic atrophy product codesHCPCS
    J2782Izervay HCPCS code J2782
    J2781Syfovre HCPCS code J2781
    HCPCS / J / Q codes mapped to products in excerptHCPCS
    J9217Referenced category/code placeholder repeated in excerpt
    J3380Entyvio IV (listed mapping)
    J1745Remicade
    Q5103Inflectra (biosimilar) or listed Q-code in excerpt
    Q9997Pyzchiva IV (Q9997 listed)
    Q5121Avsola (Q5121)
    Q5098Imuldosa IV (Q5098)
    Q9999Otulfi IV (Q9999)
    Q9998Selarsdi IV (Q9998)
    J3590Starjemza IV (J3590)
    1–10 of 20
    1/2
    Biologics entriesHCPCS
    J3380Listed repeatedly in product rows (site/admin code context)
    Q5103Inflectra HCPCS code
    Q5138Wezlana HCPCS code
    Q5134Tyruko HCPCS code
    Infliximab and biosimilarsHCPCS
    J2323Tysabri (listed)
    Q5104Renflexis HCPCS code
    Q5121Avsola HCPCS code
    J1745Remicade / unbranded infliximab HCPCS code
    Intravenous ironHCPCSCovered
    J1439Injectafer HCPCS code
    J1437Monoferric HCPCS code
    Q0139Feraheme HCPCS code
    Q0138Feraheme variant HCPCS code
    J2916Ferrlecit / sodium ferric gluconate HCPCS code
    J1750Infed HCPCS code
    J1756Venofer HCPCS code
    IVIG productsHCPCS
    J1561Gammaked / Gamunex-C HCPCS code
    J1459Privigen HCPCS code
    J1552Alyglo HCPCS code
    J1554Asceniv HCPCS code
    J1556Bivigam HCPCS code
    J1572Flebogamma HCPCS code
    J1569Gammagard Liquid / S/D HCPCS code
    J1557Gammaplex HCPCS code
    J1568Octagam HCPCS code
    J1576Panzyga HCPCS code
    SCIG and multiple sclerosis therapiesHCPCS
    J1559Hizentra HCPCS code (SCIG)
    J1558Xembify HCPCS code (SCIG)
    J1551Cutaquig HCPCS code (SCIG)
    J1555Cuvitru HCPCS code (SCIG)
    J1575HyQvia HCPCS code (SCIG)
    J2350Ocrevus HCPCS code
    J2351Ocrevus Zunovo HCPCS code
    J2329Briumvi HCPCS code
    J0202Lemtrada HCPCS code
    Immune globulins / SCIG (examples in excerpt)HCPCS
    J1559Hizentra
    J1558Xembify
    J1551Cutaquig
    J1555Cuvitru
    J1575HyQvia
    J1569Gammagard Liquid
    Multiple sclerosis agents (examples)HCPCS
    J2350Ocrevus
    J2329Briumvi
    J0202Lemtrada
    J2323Tysabri
    Breast cancer / Avastin biosimilars (examples)HCPCS
    J9316Phesgo
    J9306Perjeta
    Q5107Mvasi
    Q5118Zirabev
    J9035Avastin
    Q5107Mvasi (repeat)
    Taxane chemotherapiesHCPCS
    J9267Paclitaxel
    J9264Abraxane
    J9171Docetaxel
    Mixed oncology agents and category placeholdersHCPCS
    J9033Category placeholder (multiple agents grouped under J9033 in document)
    J9058Bendamustine
    J9056Vivimusta
    J9045Carboplatin
    J9174Beizray
    J9172Docivyx
    Herceptin and biosimilars groupHCPCS
    Q5117Kanjinti
    Q5112Ontruzant
    J9355Herceptin
    Q5146Hercessi
    Q5113Herzuma
    Q5114Ogivri
    Rituximab and multiple myeloma / other oncology agentsHCPCS
    Q5119Riabni / Rituxan group placeholder
    Q5123Riabni (alternate code listed)
    J9312Rituxan
    J9311Rituxan Hycela
    J9179Halaven
    J9352Yondelis
    Multiple myeloma agentsHCPCS
    J9046Bortezomib / Velcade
    J9047Kyprolis
    J9145Darzalex
    J9144Darzalex Faspro
    J9176Empliciti
    J9227Sarclisa
    PD-1/PD-L1 immunotherapy agentsHCPCS
    J9119Libtayo / PD-1/PD-L1 group placeholder
    J9271Keytruda
    J9299Opdivo
    J9289Opdivo Qvantig
    J9022Tecentriq
    J9024Tecentriq Hybreza
    Pemetrexed / antifolate agentsHCPCS
    J9305Alimta
    J9294Pemetrexed
    J9296Pemetrexed (other codes listed)
    J9297Pemetrexed (other codes listed)
    J9314Pemetrexed (other codes listed)
    J9304Pemfexy
    Pemetrexed / AlimtaHCPCS
    J9305Alimta
    J9294Pemetrexed (one of listed codes)
    J9296Pemetrexed (one of listed codes)
    J9297Pemetrexed (one of listed codes)
    J9314Pemetrexed (one of listed codes)
    Ophthalmic/VEGF inhibitors and related biologicsHCPCS
    C9257Bevacizumab (Avastin) - HCPCS C9257/J7999 listed
    J7999Bevacizumab (Avastin) - miscellaneous code listed
    J0178Eylea
    J0177Eylea HD
    Q5124Byooviz
    Q5147Pavblu
    Q5150Ahzantive
    Q5149Enzeevu
    J3590Eydenzelt (misc codes J3590/C9399)
    C9399Eydenzelt (misc codes J3590/C9399)
    1–10 of 17
    1/2
    Viscosupplements (single and multiple injection)HCPCS
    J7318Durolane
    J7325Synvisc-one / Synvisc
    J7326Gel-one
    J7327Monovisc
    J7322Hymovis One / Hymovis
    J7323Euflexxa
    J7328Gelsyn-3
    J7320GenVisc
    J7321Hyalgan / Supartz FX / Visco-3 (same code used)
    J7324Orthovisc
    1–10 of 13
    1/2
    Severe asthma, somatostatin analogues, systemic lupus biologicsHCPCS
    J0517Fasenra
    J2356Tezspire
    J2357Xolair
    J2786Cinqair
    J2182Nucala
    J1930Somatuline depot
    J2353Octreotide acetate depot / Sandostatin LAR
    J2502Signifor LAR
    J0490Benlysta
    J0491Saphnelo
    Oral iron trial — After intolerance to oral iron or unsatisfactory response to oral iron
    Trigger for IV iron coverageAfter intolerance to oral iron or unsatisfactory response to oral iron

    What providers must do (authorization, forms, step therapy)

    Prior Authorization

    Prior authorization requirements vary by product

    Prior authorization requirements vary by product. Some drugs explicitly require prior authorization, others do not, and many infused specialty agents are mapped to HCPCS/J‑codes with individual prior‑authorization rules. Verify the specific product-level entry and linked medical necessity criteria before ordering.

    • Prior authorization status differs by drug and indication — review the product row for Prior authorization notes (e.g., some entries show “Prior authorization” while others show “Prior authorization is not required”).
    • Many infused specialty drugs are mapped to HCPCS/J‑codes; the table rows indicate whether a prior authorization or medical necessity criteria apply for that code.
    Prior Authorization

    Prior authorization requirements for listed HCPCS products

    For listed HCPCS/J‑code products, the policy associates each product with an HCPCS code and a prior‑authorization/criteria status. Providers should use the HCPCS mapping to confirm whether a given infusion or biologic requires authorization.

    • Examples: Zoledronic acid (J3489) — prior authorization not required; Botox (J0585) — prior authorization not required for listed indications; Neulasta (J2506) — prior authorization not required.

    Initial therapy / preferred-first rules

    inv-87: Bone resorption inhibitors initial therapy

    Preferred-first requirement for bone resorption inhibitors

    Preferred-first: Preferred drugs from the specified tiers (e.g., pamidronate J2430, zoledronic acid J3489 and designated tier 2 preferred agents) must be used prior to coverage of non-preferred bone resorption inhibitors; Xgeva and other agents have linked criteria for step therapy when applicable

    Failure to trial preferred agents as indicated may result in denial; see product-level links for exact step therapy/criteria

    inv-88: Initial biologic selection

    Preferred vs non-preferred biologics — initial selection guidance

    Preferred biologics: Preferred infliximab biosimilars such as Inflectra (Q5103) and Renflexis (Q5104) are listed with linked medical necessity criteria and typically have no step therapy for some indications; non-preferred biologics or biosimilars (e.g., Avsola where designated) may be subject to step therapy per the linked criteria

    Refer to product-level 'Step therapy criteria' links for specific indications and exceptions

    Step therapy rules and tables

    Step therapy requirementSummary
    Try preferred product(s) first per category before non-preferred product will be covered
    Preferred products listed for a category must be used prior to coverage of non-preferred agents; exception process exists for specific cases
    Applies to indicationsPreferred agents / Non-preferred examples
    Anemia due to Zidovudine use in HIV; transfusion reduction for select surgeries; other anemia indications noted as subject to step therapy
    Preferred: Procrit, Aranesp. Non-preferred examples: Epogen, Retacrit, Vafseo (Retacrit referenced HCPCS J0885/Q5106)
    Product / Indication flaggedPreferred vs non-preferred status
    Multiple product and indication entries are labeled 'Indications subject to step therapy' (examples include Crohn's disease, ulcerative colitis, gender dysphoria and others)
    Document identifies preferred drugs for categories and lists non-preferred alternatives; preferred status shown in product rows while some non-preferred products reference linked step therapy criteria
    Linked step therapy entriesImplication
    Multiple products explicitly include 'Step therapy criteria = Link to criteria' such as Avsola, Remicade, unbranded infliximab and some IV iron products (e.g., Feraheme, Injectafer, Monoferric)
    Providers must follow the linked step therapy criteria (and submit fax/request forms as indicated) before non-preferred product coverage is approved
    Categories / agents notedStep therapy note
    Numerous categories and agents flagged as 'Indications subject to step therapy' including Rituxan and biosimilars (all requests except rheumatoid arthritis) and PD‑1/PD‑L1 agents (e.g., Keytruda, Opdivo, Tecentriq) for specified indications
    Exceptions are listed where applicable (e.g., rheumatoid arthritis excluded for rituximab); many immunotherapy/biologic categories require following step therapy criteria per linked documents
    Products/categories with external step therapy rulesReference
    IV iron products (Feraheme Q0139/Q0138, Injectafer J1439, Monoferric J1437) and some infliximab/biosimilar entries (Avsola Q5121, Remicade J1745) list step therapy criteria as a link to separate criteria documents
    Specific step therapy rules and fax request forms are provided via 'Link to criteria' / 'Link to fax form' referenced in the product rows and must be consulted for coverage decisions

    Biosimilar listings and callouts

    Note
    Note
    Note
    Note
    Note
    Note
    Note

    Policy scope and document notes

    This document groups Part B (medically administered) drugs by therapeutic category and identifies preferred and non‑preferred products, maps products to HCPCS/J/Q codes, and indicates applicable utilization management such as step therapy and prior authorization. The listings provide links to product‑specific medical necessity and step therapy criteria and to fax request forms where applicable; providers should use those links when requesting non‑preferred drugs or when PA is required.

    Key definitions

    Step therapy — A utilization management requirement that a preferred drug must be tried before a non-preferred alternative will be covered.
    DefinitionA utilization management requirement that a preferred drug must be tried before a non-preferred alternative will be covered.
    PurposeEnsure preferred products are used first; exception process exists for patients who require a non-preferred product.
    Where to find specific rulesSee corresponding step therapy criteria document on the Aetna website for product- and indication-specific requirements.
    Prior authorization — Administrative requirement indicated for many specialty infused drugs in this section; referenced by 'Prior authorization is not required...'
    DefinitionAdministrative requirement indicated for many specialty infused drugs; entries show 'Prior authorization is not required' or link to criteria when PA is required.

    Document changes and history

    ©2025copyrightLatest

    Document copyright year updated to 2025 per Aetna Inc. notice

    2025-01-01revision

    Policy document version reference updated (document code 4168504-01-01) per Aetna notice

    Policy Summary
    PayerAetna
    PolicyMedicare Part B preferred drug list — Aetna Medicare Advantage (MA) only plans
    Policy CodePolicy N/A
    Change TypeNo material changes
    Effective DateN/A
    Next Review DateN/A
    Key ActionUse the linked medical necessity criteria and fax prior authorization forms when requesting non-preferred or PA-required Part B drugs.
    SourceLink
    On This Page
    Coverage criteria and product-specific rulesHCPCS/J-code mapping and code tablesWhat providers must do (authorization, forms, step therapy)Initial therapy / preferred-first rulesStep therapy rules and tablesBiosimilar listings and calloutsPolicy scope and document notesKey definitionsDocument changes and history
    Alternate IV iron indicationIron deficiency anemia in patients who have chronic kidney disease
    Context of requirementListed under 'Category: Intravenous iron' as an indication subject to step therapy
    Rituximab step therapy exception — All requests except rheumatoid arthritis are subject to step therapy
    Scope of step therapy for rituximabAll requests for rituximab and biosimilars are subject to step therapy except rheumatoid arthritis
    Exception statedRheumatoid arthritis requests are excluded from the step therapy requirement
    Location in documentNoted within the 'Category: Rituxan and biosimilars' / related IV iron section
    Tiered-preference requirement — Preferred product from both tiers required prior to non-preferred ophthalmic VEGF product
    Tiered-preference rulePreferred product from both tiers required prior to receiving a non-preferred ophthalmic VEGF product
    First-tier exampleBevacizumab (Avastin) is listed as a 1st tier preferred drug with 'prior authorization is not required' for the listed entries
    Second-tier exampleByooviz is listed as a 2nd tier preferred drug after trial/failure of bevacizumab
  1. Many biologics and biosimilars are shown with HCPCS codes (e.g., Inflectra Q5103, Renflexis Q5104, Avsola Q5121, Remicade J1745) and a linked criteria/fax form entry.
  2. Documentation Required

    Prior authorization and HCPCS mapping

    HCPCS/J‑code mapping and prior‑authorization notes are presented together; use the HCPCS code in the policy row to locate the corresponding medical necessity criteria and the required fax/prior‑authorization form.

    • When the row lists a Link to criteria and Link to fax form, providers must submit the documented clinical information via the specified form.
    • If a row shows “Prior authorization is not required,” no prior authorization/fax form is needed for that HCPCS code for the listed indication.
    Step Therapy

    Prior authorization for IV iron

    Intravenous iron products have mixed requirements: older formulations often do not need prior authorization while newer IV iron agents (Injectafer, Monoferric, Feraheme) are subject to step‑therapy criteria and require submission of the step therapy documentation.

    • No prior authorization required: Ferrlecit (J2916), Sodium ferric gluconate (J2916), Infed (J1750), Venofer (J1756).
    • Step therapy / prior authorization required: Feraheme (Q0139/Q0138), Injectafer (J1439), Monoferric (J1437) — see and follow the step therapy criteria and submit the linked fax request form.
    Prior Authorization

    Prior authorization for infliximab and biosimilars

    Infliximab and its biosimilars have specific guidance: multiple infliximab products are mapped and may be subject to step‑therapy or medical necessity criteria. Follow the linked criteria and fax forms for authorization.

    • Examples: Inflectra (Q5103) and Renflexis (Q5104) show links to medical necessity criteria and fax forms; Avsola (Q5121) and Remicade (J1745) may require step therapy or criteria per the product row.
    • Unbranded infliximab entries reference J1745 with explicit links to medical necessity criteria and fax request forms — submit required documentation when requested.
    Prior Authorization

    Prior authorization requirements (mixed)

    Requirements across categories are mixed. Some cytotoxics and supportive care agents explicitly state that prior authorization is not required, while many biologics, immunologics, and specialty infusions reference linked criteria and forms.

    • Prior authorization not required examples: Docetaxel (J9171), certain erythropoiesis‑stimulating agents (some Procrit/ Epogen entries).
    • Many immunologics/biologics list a Link to criteria and Link to fax form — treat these as authorization required until the row indicates otherwise.
    Note

    Not explicitly stated in this excerpt

    Some rows in the excerpt are incomplete or do not explicitly state prior authorization status. When the policy row lacks a clear prior‑authorization note, providers must consult the linked medical necessity criteria or contact Aetna using the number on the member's ID card before proceeding.

    • If a product row does not state “Prior authorization is not required” or list a link to criteria, assume authorization may be required and verify before administration.
    • Use the payer resources (website links or provider phone line) when table entries are ambiguous or missing.
    Denial Risk

    Denial risk for step therapy noncompliance

    Failure to follow step‑therapy requirements or to obtain required prior authorization may lead to claim denial or non‑coverage. Providers should ensure preferred products and tier‑specific requirements are met before requesting non‑preferred agents.

    • Step‑therapy denials can occur if preferred Tier 1 and Tier 2 products are not tried and documented where the policy requires both tiers prior to non‑preferred use (e.g., bone resorption inhibitors, VEGF ophthalmic inhibitors).
    • When a product row indicates “Indications subject to step therapy,” follow the referenced step therapy criteria to avoid denials.
    Denial Risk

    IV iron step therapy denial risk

    IV iron agents listed with step‑therapy language require adherence to the step‑therapy criteria; absent required trials or documentation, requests for Injectafer, Monoferric, or Feraheme may be denied.

    • For Feraheme (Q0139/Q0138), Injectafer (J1439), Monoferric (J1437) — submit the step‑therapy documentation listed in the policy; lack of required prior trials may result in denial.
    • For IV iron products without step therapy (e.g., Ferrlecit, Venofer), prior authorization is not required per the product row.
    Denial Risk

    Denial risk for missing medical necessity/step therapy

    Coverage decisions frequently depend on medical necessity documentation. Always use the linked medical necessity criteria and the specified fax/prior‑authorization form to submit supporting clinical information.

    • Many product rows include Link to criteria and Link to fax form — use those documents when preparing prior‑authorization requests.
    • If an entry lists a fax request form, the provider must submit that form with the required clinical details; incomplete forms may delay or deny authorization.
    Documentation Required

    Use linked medical necessity criteria and fax forms

    Use the links to medical necessity criteria and the payer's fax request forms for all products that reference them. These documents define indication‑specific requirements, step‑therapy pathways, and required clinical documentation to support authorization.

    • Where the table shows Link to criteria — open and follow the medical necessity criteria for the exact indication.
    • Where the table shows Link to fax form or “Fax request form” — complete and submit the specified form; many biologics and specialty infusions require this submission.
    Documentation Required

    Submission forms and links

    Submission forms and links are provided throughout the policy for many infused and specialty agents. Providers must submit the specified fax request form and reference the HCPCS code and clinical criteria on the form.

    • The policy rows that include both an HCPCS code and a Link to fax form indicate that the payer expects the corresponding form for prior‑authorization review.
    • Include the HCPCS/J‑code when submitting the fax form to ensure correct routing and adjudication.
    Documentation Required

    Fax form and medical necessity documentation

    When a row lists a Fax request form or Link to fax form, that indicates required documentation for prior‑authorization review. Complete clinical fields, attach supporting records, and submit via the method specified on the form.

    • Fax forms are the operational mechanism for many prior‑authorization requests in this policy excerpt — incomplete or missing attachments can delay review.
    • Follow any form‑specific instructions (e.g., number of prior treatment attempts, lab values, prior response) as detailed in the linked criteria.
    Documentation Required

    Use linked criteria/fax forms

    Consolidate: always use the linked criteria and fax forms where provided. These are authoritative — they state whether prior authorization is required, what clinical prerequisites (including step‑therapy) must be met, and what documentation to submit.

    • If a product row includes both a criteria link and a fax form link, submit the fax form with the specific evidence requested by the criteria.
    • If the product row indicates “Prior authorization is not required,” no fax form is needed for that indication; document the basis in the medical record.
    Documentation Required

    Required documentation and forms

    Required documentation and forms are noted at the product level. Providers should not assume coverage; follow the policy row, complete required forms, and supply all clinical documentation to avoid delays or denials.

    • Required elements often include the HCPCS/J‑code, indication, prior treatment history, and relevant labs/imaging as specified in the linked criteria.
    • When in doubt, contact Aetna via the provider phone number on the member ID or use the website links included in the policy to obtain the correct form or criteria.
    Step Therapy

    Step therapy required for some indications

    Step therapy applies to many categories and specific indications in this excerpt. For affected indications, preferred products or multiple tier trials may be required before coverage of non‑preferred agents.

    • Examples of indications subject to step therapy: anemia related to zidovudine use (ESAs), multiple bone resorption indications, Crohn's disease, psoriasis, and many immunotherapy/biologic categories.
    • Some categories require trying preferred products from both tiers prior to a non‑preferred drug (e.g., VEGF ophthalmic inhibitors, select bone resorption inhibitors).
    Step Therapy

    Step therapy applies to specified indications

    Step therapy applies to specified indications; consult the row for the indication and the linked step therapy criteria to confirm required prior agents, trial durations, and documentation.

    • Policy lists indications subject to step therapy (for example: Crohn's disease, ulcerative colitis, selected oncology indications, and certain supportive care uses).
    • When the row references a Link to criteria for step therapy, adhere to the sequence and evidence requirements there to ensure coverage.
    Step Therapy

    Step therapy for various biologics

    Many biologics and immunotherapies are explicitly labeled as “subject to step therapy.” Providers must follow the step therapy pathway in the referenced criteria before requesting non‑preferred biologics.

    • Categories with step therapy examples include Rituxan and biosimilars, PD‑1/PD‑L1 agents, and multiple immunologics listed under J9217/J3380 groupings.
    • Where a biologic row shows step‑therapy links, document prior trials of preferred agents and outcomes on the fax form.
    Step Therapy

    Step therapy applies to many immunotherapies/biologics

    Step therapy applies broadly across many immunotherapies and biologics in this document. For these agents, the policy often requires prior trials of preferred products and submission of linked authorization forms.

    • PD‑1/PD‑L1 agents and multiple monoclonal antibodies show indications subject to step therapy (e.g., squamous cell carcinoma, metastatic disease indications).
    • Follow the linked criteria for immunotherapy classes to confirm the required sequence of therapy and documentation needed.
    Step Therapy

    Step therapy references

    The policy references multiple step‑therapy criteria documents. Treat these references as binding — they describe the required sequence, number of prior agents, and clinical thresholds for coverage decisions.

    • When a row shows “Step therapy criteria = Link to criteria,” consult that document for exact trial requirements, timeframes, and exceptions.
    • Use the step therapy reference to guide initial prescribing, prior authorization requests, and appeals if coverage is denied.
    Provider action
    Providers should follow the 'Link to criteria' and submit the referenced fax request form when prior authorization is indicated for a product.
    ExamplesSome products (e.g., Lupron depot, Trelstar, Zoladex) are explicitly noted as 'Prior authorization is not required' in product rows; others (e.g., infliximab group) include 'Link to criteria' and fax forms.
    HCPCS/J-code mapping — The document maps drug product names and biosimilars to specific HCPCS/J-codes (e.g., Remicade = J1745, Entyvio IV = J3380, multiple Q-co...
    DefinitionDocument maps drug product names and biosimilars to specific HCPCS/J-codes (examples: Remicade = J1745; Inflectra = Q5103; Byooviz = Q5124).
    UsageHCPCS/J-code mapping is shown in each product row alongside links to medical necessity, step therapy criteria, and fax forms.
    Examples from VEGF and infliximab groupsBevacizumab (Avastin) = C9257/J7999; Remicade = J1745; Inflectra = Q5103; Avsola = Q5121.
    Step therapy — A coverage policy approach where preferred drugs must be used first and non-preferred or certain products require meeting specific medica...
    DefinitionA coverage policy approach where preferred drugs must be used first and non-preferred or certain products require meeting specific medical necessity or step therapy criteria before coverage is approved.
    ImplicationFailure to meet step therapy requirements may result in denial of coverage for the requested non-preferred product.
    ApplicationUsed across many categories (e.g., infliximab/biosimilars, IV iron, ophthalmic VEGF inhibitors) with product-level links to criteria.
    Formulary listing note — Listed products are informational, trademarks acknowledged, subject to change, and do not replace prescriber clinical judgment.
    Formulary noteListed products are informational, trademarks acknowledged, subject to change, and do not replace prescriber clinical judgment.
    Document scopeFormulary designations and preferred statuses may change due to new launches, approvals, or market changes; see Evidence of Coverage for plan details.
    Provider responsibilityPrescribers should use clinical judgment and follow linked medical necessity/step therapy criteria and fax forms where applicable.